MOTS-C vs retatrutide: how the two are studied
MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied in metabolic signalling; retatrutide is a synthetic triple GIP/GLP-1/glucagon receptor agonist in registered clinical trials. The comparison is one of compound class and evidence tier, and no published study has administered the two together.
MOTS-c vs retatrutide is a comparison of two compounds that sit in different classes and at different evidence tiers, so the useful comparison is of how each is researched rather than of competing results. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the mitochondrial 12S rRNA gene; retatrutide, development code LY3437943, is a synthetic single-molecule peptide with agonist activity at the GIP, GLP-1 and glucagon receptors.
This article answers the plain comparison question, sets out why MOTS-c with retatrutide has no published combination literature, and explains what the string omegamino retatrutide refers to. It is written for a reader who has met both names in the same search results and wants to know whether the pairing reflects published work. Preparation, handling and administration are out of scope, and no amount or schedule appears on this page. The full citation lists live at the MOTS-c and retatrutide evidence records, which this article links to rather than restates.
Key takeaways
- MOTS-c and retatrutide belong to different compound classes: a mitochondrial-derived peptide against a synthetic single-peptide triple receptor agonist.
- The study records differ in kind, not only in size: controlled rodent and cell-culture work plus observational human measurements for MOTS-c, against registered randomised trials for retatrutide.
- No published study administers MOTS-c together with retatrutide in any model, so MOTS-c with retatrutide has no combination literature.
- Omegamino retatrutide does not appear in any source consulted here and is not a chemical name, a development code or a receptor class; the resolvable part of the string is the compound name.
- As of August 2026 neither compound was an approved medicine in any jurisdiction.
MOTS-c vs retatrutide: the short answer
MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame inside the mitochondrial 12S rRNA gene, mitochondrial rather than nuclear DNA, and belongs to the mitochondrial-derived peptide family alongside humanin and the SHLP peptides. Retatrutide is a synthetic single-molecule peptide with agonist activity at three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the GLP-1 receptor and the glucagon receptor.
The practical difference is not chemistry alone. Retatrutide's record is built from randomised, double-blind, placebo-controlled trials with pre-specified primary endpoints and ClinicalTrials.gov registration numbers. MOTS-c's interventional record is built from controlled rodent and cell-culture experiments; the human work measures endogenous MOTS-c rather than giving the peptide.
| Attribute | MOTS-c | Retatrutide |
|---|---|---|
| Compound class | Mitochondrial-derived peptide (mitokine) | Synthetic single-peptide triple receptor agonist |
| Origin | 16 amino acids encoded in the mitochondrial 12S rRNA gene | Engineered on a GIP backbone; development code LY3437943 |
| Signalling studied | Folate, AICAR and AMPK axis, mitochondrial-to-nuclear retrograde signalling, direct CK2 binding | GIP, GLP-1 and glucagon receptor agonism |
| Interventional human data | None; no trial has given the peptide to humans | Phase 1b, phase 2 and a first phase 3 readout published; registrational phase 3 programme ongoing |
| Human observational data | Circulating levels measured as a candidate biomarker; one mitochondrial genotype association | Not applicable; the compound is not endogenous |
| Trial registration | None for the peptide itself | NCT04867785 and NCT04881760; TRIUMPH and TRANSCEND programmes |
| Regulatory status, August 2026 | Not approved; an FDA compounding advisory committee recommended 503A Bulks List addition on a divided vote, July 2026 | Not approved in any jurisdiction |
MOTS-c: a peptide encoded in mitochondrial DNA
The research record gives MOTS-c a molecular formula of C101H152N28O22S2 and a molecular weight of 2174.6 g/mol, sourced from the PubChem record and describing the free base. The record notes that lyophilised peptide is normally supplied as an acetate or trifluoroacetate salt and carries residual water, so the mass of powder in a vial is not the same quantity as the molecular weight implies.
Mechanistically, the discovery work describes inhibition of the folate cycle and the de novo purine biosynthesis tethered to it, causing accumulation of the intermediate AICAR and consequent activation of AMP-activated protein kinase. Later studies report translocation of the peptide from the mitochondrion to the nucleus under metabolic stress, where it associates with stress-responsive transcription factors and regulates a nuclear gene programme. Direct binding of casein kinase 2 has also been described, activating the enzyme in skeletal muscle while suppressing it in adipose tissue. That retrograde, mitochondrial-to-nuclear arrangement is what distinguishes this family from nuclear-encoded peptides.
The human record is different in kind rather than merely thinner. Circulating MOTS-c has been measured as a candidate biomarker across metabolic, cardiovascular, renal and reproductive conditions, and a mitochondrial variant in the coding region, m.1382A>C, producing a K14Q substitution, has been associated with type 2 diabetes prevalence in East Asian men, with the association concentrated in men reporting low physical activity. The biomarker direction is not consistent: a systematic review and meta-analysis of seven studies reported lower circulating concentrations in diabetes and obesity overall, while subgroup analysis showed the direction differed, reduced in diabetes and increased in obesity. A separate 2026 cross-sectional comparison reported higher levels in adults with obesity and no change after surgical weight loss, and a 2026 study in polycystic ovary syndrome reported lower serum levels than matched controls. The research record notes that assay standardisation is inconsistent between studies.
No randomised controlled trial has administered exogenous MOTS-c to humans, so its behaviour in people is not characterised. The research record states that long-term safety and any functional benefit in humans remain unestablished.
One regulatory development is routinely misread. On 23-24 July 2026 the FDA's Pharmacy Compounding Advisory Committee considered MOTS-c for the 503A Bulks List and recommended its addition on a reported vote of 7-5 with two abstentions. The committee advises and does not decide; the recommendation is not binding, the FDA has not completed the rulemaking that would change anything, and inclusion on the list would govern pharmacy compounding, a separate activity from research-use-only supply. The recommendation is not an approval of a drug.
Retatrutide: a synthetic triple receptor agonist in registered trials
Retatrutide is described in the cited trials as a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide, GLP-1 and glucagon receptors. The discovery work characterises it as built on a GIP backbone and acylated with a C20 fatty-diacid moiety that supports albumin binding and the extended half-life reported in pharmacokinetic work. Receptor-level studies describe an imbalanced agonist: potency at the GIP receptor exceeds potency at the GLP-1 and glucagon receptors relative to the native ligands.
The study record is a registered clinical programme. Two phase 2 randomised, double-blind, placebo-controlled trials are cited with this article: a trial in 281 adults with type 2 diabetes, registered as NCT04867785 and also active-comparator-controlled, and a 48-week trial in 338 adults with obesity, registered as NCT04881760. Reported adverse events across the programme were predominantly gastrointestinal; the obesity trial also described increases in heart rate that peaked at 24 weeks and declined thereafter.
Beyond those reports, the programme has published design papers for the registrational TRIUMPH trials and for the TRANSCEND programme, and a first phase 3 readout appeared in 2026. The research record states that as of August 2026 retatrutide was not an approved medicine in any jurisdiction, and that long-term safety, cardiovascular outcome data and durability of effect after discontinuation are not established in peer-reviewed reports.
Is MOTS-c studied with retatrutide?
No published study was identified that gives MOTS-c together with retatrutide in any model. The two PubMed records cited with this article name retatrutide alone: one is the phase 2 trial in type 2 diabetes, the other the phase 2 obesity trial. The MOTS-c evidence record summarises 15 published studies, none of which carries a retatrutide arm. Searches that surface both names together reflect co-occurrence in the same market and the same search results, not a study design.
There is also a structural reason the pairing does not appear. The two compounds act through unrelated mechanisms, a mitochondrially encoded signalling peptide studied through AMPK and one-carbon metabolism on one side, and a G protein-coupled receptor agonist studied through three defined receptors on the other, so there is no shared receptor axis for a combination study to interrogate. The interventional data on MOTS-c come from rodent and cell-culture models, which would be the natural setting for a combination experiment; none has been published.
That absence is a statement about the literature, not about the compounds, and it is why this comparison is drawn at class level: there is no combined dataset to compare. An existing research-comparison summary sits at retatrutide vs MOTS-c; this article answers the plainer vs and with forms of the question, and the naming variant below.
What omegamino retatrutide refers to
The string omegamino retatrutide does not appear in either of the PubMed abstracts cited with this article, in the retatrutide research record, in the product record or in the published certificate for the compound. It is not a chemical name, an international nonproprietary name, a development code or a receptor class.
The resolvable part of the string is the compound name. Retatrutide is the molecule the literature also calls LY3437943, and the catalogue entry for the same product notes that it is often searched as GLP-3 or reta. The certificate published for batch 26138 shortens the name further, carrying the results string "RT: 30mg | Purity: 99.86%". A leading token of the kind seen in omegamino retatrutide is a vendor or catalogue prefix attached in front of that compound name; no source consulted here attaches it to a distinct molecule, and it does not function as an identifier the way a development code does.
Because such a prefix is not a controlled identifier, it is a poor way to specify material. The compound name and the certificate results line identify the substance; the batch number and test date identify the batch.
How each compound is documented on a batch certificate
Both compounds are supplied as lyophilised powder for laboratory research and are labelled not for human or veterinary use. Each carries a certificate published from a named laboratory outside the supplier. The MOTS-c certificate covers batch 26158, tested 6 August 2026 by the Brown Institute of Biomolecular Research, with the results string "MOTS-C: 40mg | Purity: 99.79%". The retatrutide certificate covers batch 26138, tested 10 August 2026 by the same laboratory, with the results string "RT: 30mg | Purity: 99.86%".
- 01
A certificate reports measurements for one batch
Principally identity and chromatographic purity, and it applies to that batch alone.
- 02
A certificate cannot compare two compounds
It carries no evidence tier and says nothing about whether a substance has been studied in humans.
- 03
Chromatographic purity is a peak-area ratio
It is taken from the chromatogram, not a statement of how much compound is present by weight.
- 04
Batch number and test date identify the material
Those two fields, not the compound name alone, say which report covers which material.
- 05
The full report is published and archived
Each batch report is published on the product record and archived at /lab/coa.
Common questions.
- What is the difference between MOTS-c and retatrutide?
They differ in class and in evidence tier. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the mitochondrial 12S rRNA gene, studied through AMPK signalling, folate and methionine one-carbon metabolism and mitochondrial-to-nuclear retrograde signalling. Retatrutide is LY3437943, a synthetic single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors, studied in registered phase 1, phase 2 and phase 3 trials. The two share no receptor target and no clinical trial.
- Has MOTS-c been studied with retatrutide?
No published combination study was identified. The two PubMed records cited with this article name retatrutide alone, and the MOTS-c evidence record summarises 15 published studies, none of which carries a retatrutide arm. No combined data appear in any model, including rodent work. That is an absence in the literature rather than a finding about the pair.
- What is omegamino retatrutide?
The string does not appear in the cited PubMed abstracts, the retatrutide research record, the product record or the published certificate. It is not a chemical name, an international nonproprietary name, a development code or a receptor class. The resolvable part of the string is retatrutide, development code LY3437943, which the catalogue entry for the same product also lists under the search aliases GLP-3 and reta.
- Does MOTS-c have clinical trial data?
No randomised controlled trial has administered exogenous MOTS-c to humans. The human record is observational: circulating MOTS-c measured as a candidate biomarker across several conditions, plus one mitochondrial genotype association (m.1382A>C, K14Q) with type 2 diabetes risk in East Asian men. In July 2026 the FDA's Pharmacy Compounding Advisory Committee considered MOTS-c for the 503A Bulks List and recommended its addition on a reported vote of 7-5 with two abstentions. That recommendation is not an approval, is not binding, and governs pharmacy compounding rather than research supply.
- Are MOTS-c and retatrutide both approved medicines?
No. The retatrutide research record states that as of August 2026 the compound was not an approved medicine in any jurisdiction. MOTS-c holds no approval either; the July 2026 advisory committee vote concerns pharmacy compounding under section 503A, which is a separate activity, and the FDA has not completed the rulemaking that would formally change anything.
Sources
- 01Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
- 02Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- 03Buy MOTS-c 40mg: Batch COA · AKH BioLabs
- 04MOTS-C research — published studies and evidence · AKH BioLabs
- 05Buy Retatrutide 30mg (GLP-3, Reta): Price & COA · AKH BioLabs
- 06Retatrutide research — published studies and evidence · AKH BioLabs